Special Issue "Zebrafish: The Key for Cancer Treatment"
Deadline for manuscript submissions: 31 July 2017
Zebrafish has been used since the early 1970s in Oregon as a model organism for vertebrate development and gene function. Over the past few years, zebrafish has emerged as a cancer model that complements the murine system. This model was discovered in cancer research with cancer currently being the second cause of death worldwide. It has been increasingly used in subsequent years due to the exponential growth of cancer, especially in developed countries. By virtue of its experimental swiftness, low cost maintenance and high-throughput advantages against the murine model, the zebrafish has had a high impact on research.
Covering areas ranging from biochemistry or genetics, to toxicology or xenotransplantation, zebrafish is a useful tool to discover some of the most important underlying mechanisms of cancer proliferation, migration and metastasis. Using this small fish, researchers from all over the world are able to gather information in a very efficient way to fight against this heterogeneous disease.
In this Special Issue, we would like to invite submissions of original research or review articles on any topic related to “Zebrafish: The Key for Cancer Treatment”. We thereby hope to gather knowledge to find critical steps for cancer treatment using this model organism. We look forward to receiving your contributions.
Dr. Laura Sánchez
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- model organism
- high throughput
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Working Title: Finding novel cancer therapies using zebrafish.
Putative Authors: Aurora Idilli, Francesca Precazzini, Marina Mione and Viviana Anelli
Affiliations: Laboratory of Experimental Cancer Biology, Cibio, University of Trento, Via Sommarive 9, Trento, Italy
Abstract: Over the past 15 years, zebrafish has emerged as a powerful tool for studying human cancers. Transgenic techniques have been employed to model leukemia, rhabdomyosarcoma, melanoma and glioblastoma. These models present histopathological and molecular conservation with their human cancer counterparts and have been fundamental for understanding mechanisms of tumor initiation and progression. Moreover, xenotrasplantations of human cancer cells in embryos, juvenile or adults zebrafish offer the advantage of studying the behavior of human cancer cells in a live organism. Chemical-genetic screens using zebrafish embryos have uncovered novel drug pathways and new therapeutic strategies, some of which are now tested in clinical trials.
Working Title: Emerging estrogenic pollutants in the aquatic environment and breast cancer.
Putative Authors: Sylvain Lecomte, Denis Habauzit, Farzad Pakdel*
Affiliations: Research Institute in Health, Environment and Occupation (Irset), Inserm U1085, Team TREC-Transcription, Environment and Cancer, University of Rennes 1, France
*Corresponding Author: Farzad PAKDEL (firstname.lastname@example.org)
Abstract: Over the past five decades, the number of industrial chemicals in the aquatic environment has considerably increased. Among these contaminants, endocrine disrupting chemicals (EDCs) represent a significant part. These kind of compounds interfere with normal hormonal processes through multiple molecular pathways. They represent therefore a potential risk for human and wildlife as they are suspected to be involved in the development of diseases such as reprotoxicity, metabolic disorders and cancers. Indeed, several studies have suggested that the increase of breast cancer in industrialized country are linked to EDCs, particularly estrogen-like compounds. In cell, estrogen receptors (ERs, ERalpha and ERbeta) are the main targets of these compounds. More than 70% of breast cancer cells express ERalpha and their growth is influenced by estrogenic compounds. It is therefore important to characterize the estrogenic potential in surface water and to identify the molecules responsible for the hormonal effect. This would give us the possibility to prevent their effects on the breast tissue. The aim of this review is to make an overview of the emerging environmental estrogen-like compounds in the environment, to sum up the studies that evidence their direct or indirect interactions with ERs and their potential involvement in breast cancer development. Finally, we also summarize the use of in vitro and in vivo methods and models such as zebrafish, in the identification and characterization of environmental estrogens.
Working Title: The zebrafish as a model for skin cancer: a new tool for drug development.
Putative Authors: Carlo Pincelli, Annalisa Saltari and Elisabetta Palazzo
Affiliations: School of Medicine, University of Modena and Reggio Emilia, Modena, Italy
Abstract: Danio rerio, commonly known as zebrafish, is considered a promising model for the study of the mechanisms underlying tumor development, treatment efficacy and drug resistance. Given the advantages in terms of low costs, high genetic homology to humans, easy handling and transparent body for live imaging, the zebrafish has been employed to study and reproduce a broad spectrum of human tumours, including melanoma and squamous cell carcinoma (SCC). The zebrafish models for cutaneous neoplasia have been generated with different strategies including injection of cancer cells, tumour induction through chemical carcinogens and genetic manipulation. Exciting data have been recently published in melanoma by using the innovative genome-engineering Crispr/Cas9 (clustered regularly interspaced short palindromic repeats) and TALENs (transcription activator-like effectors) technologies. In the last decades, the acquisition of new genetic and transcriptomic data has led to the identification of potential targets for the treatment of skin cancer prompting the need of in vivo models for toxicological tests on large scale. To this purpose, given its higher fecundity in comparison to mouse models, the zebrafish represents an ideal tool for high-throughput drug screening. The present review focuses on the applications of zebrafish for the study of melanoma and SCC and summarizes the main findings on skin cancer initiation, relapse and drug resistance. Moreover, it highlights the progress and future perspectives for its employment as an innovative platform for the screening of small molecules and compounds.
Working Title: Cross talk between TP53 and c-MYC in the pathophysiology of Diamond-Blackfan anemia: Evidence from RPL11-deficient in vivo and in vitro models.
Putative Authors: Anirban Chakraborty1*, Tamayo Uechi2, Yukari Nakajima2, Hanna T. Gazda 3,4, Pierre-Emmanuel Gleizes5,6 and Naoya Kenmochi2*
Affiliations: 1Department of Biomedical Sciences, NU Centre for Science Education & Research, Nitte University, Mangalore-18, India
2Frontier Science Research Center, University of Miyazaki, Kiyotake, Miyazaki, Japan
3Division of Genetics and Program in Genomics, The Manton Center for Orphan Diseases Research, Children’s Hospital Boston, Boston, Massachusetts
4Harvard Medical School, Boston, Massachusetts
5Laboratoire de Biologie Moléculaire Eucaryote, Université de Toulouse, UPS, F-31000 Toulouse, France
6CNRS, UMR 5099, F-31000 Toulouse, France
* Corresponding author
Abstract: The synthesis of ribosomes is a major metabolic activity in cells. Mutations in genes encoding ribosomal proteins have been identified in Diamond Blackfan anaemia; DBA, a rare genetic disorder that presents with a prominent phenotype involving the erythroid component of the hematopoietic lineage. Impaired ribosome biogenesis causes nucleolar stress that triggers a TP53-signaling pathway, which plays an important role in the pathophysiology of DBA. Several ribosomal proteins, particularly RPL11, take part in mediating this TP53 response. However, RPL11 is one of the mutated RPs in DBA and previously, we showed that Rpl11 deficiency in zebrafish activates the Tp53 pathway. Interestingly, RPL11 also controls the transcriptional activity of c-MYC, an oncoprotein that positively regulates ribosome biogenesis. In this study, we explored the role of c-Myc in cellular and animal models to gain further insights into the mechanisms of Tp53 induction in response to RPL11 deficiency. c-Myc and several c-Myc target nucleolar proteins, including those that bind to MDM2 or modify p53, showed upregulation and increased localization in the head region of Rpl11-deficient zebrafish, where the morphological abnormalities and tp53 expression were more pronounced. Rpl11-deficient zebrafish also exhibited defects in ribosome biogenesis. However, co-inhibition of Tp53 did not alleviate the erythroid aplasia in these fish. Interestingly, in cells derived from peripheral blood of RPL11 mutated DBA patients, the ribosome biogenesis was defective but the expression level of c-Myc and its target nucleolar proteins was unchanged. The results of this study suggest a model in which increased synthesis of c-Myc target nucleolar proteins triggers a p53 response in RPL11 deficiency. Our results further demonstrate that this induction of Tp53 mediates only the morphological, but not the erythroid defects, associated with RPL11 deficiency.
Working Title: RecQ1 helicase silencing slows proliferation of U87 glioblastoma cells in the zebrafish embryonic brain.
Putative Authors: Katja Hrovat1, Miloš Vittori2, Tamara Lah Turnšek1
Affiliations: 1 National Institute of Biology, Ljubljana, Slovenia
2 Department of Biology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia
Abstract: In this study, the proliferation of U87 cells in which the expression of RecQ1 helicase has been experimentally reduced is compared to the proliferation of sham-transfected U87 cells. In vitro measurments of cell proliferation are compared with in vivo measurments in the brain and yolk sac of zebrafish embryos during a three-day period. Decreased proliferation was observed in vitro as well as in the zebrafish brain, whereas U87 cells do not readily proliferate in the yolk sac, resulting in no visible effect of RecQ1 depletion. This is the first in vivo confirmation of RecQ1 as a potential therapeutic target in the treatment of glioblastoma.
Working Title: Co-implantation with glioblastoma stem-like cells influences the invasion of U87 glioblastoma cells in zebrafish embryos.
Putative Authors: Miloš Vittori1, Barbara Breznik2, Tamara Lah Turnšek2
Affiliations: 1 Department of Biology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia
2 National Institute of Biology, Ljubljana, Slovenia
Abstract: We assessed the proliferation and invasion of U87 cells and the CD133+ glioblastoma stem-like cell line NCH421k in the brain of zebrafish embryos. Our results demonstrate that the co-implantation of both cell types strongly affects the invasion of U87 cells, quantified by measurements of relative cell dispersion and the frequency of invading cells, whereas it does not affect the invasion of NCH421k cells. The two cell lines are inhomogeneously distributed in the tumours, with each cell type occupying a well defined region of the tumour. These results are compared with the behaviour of U87 cells when co-implanted with mesenchymal stem cells.